KRAS and non-small cell lung carcinoma: Phase 1 and 2 clinical trials demonstrated significant tumor reduction in patients with G12C KRAS-positive NSCLC, with an objective response rate (ORR) of about 37% and a median PFS of 6.8 months [180,181,182,183].